Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.46 |
| ▸ | MAOA | P21397 | 8/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14432643 | 0.87 | CALML3 (0.47) | CALML3MAOACYP2C19CYP3A4MAOB | |
| SCHEMBL6023709 | 0.86 | CALML3 (0.56) | CALML3MAOACYP2C19CYP3A4MAOB | |
| SCHEMBL6023022 | 0.83 | CALML3 (0.52) | CALML3MAOACYP2C19CYP3A4MAOB | |
| SCHEMBL6030664 | 0.83 | CALML3 (0.52) | CALML3MAOACYP2C19CYP3A4MAOB | |
| SCHEMBL13528049 | 0.83 | CALML3 (0.54) | CALML3MAOACYP2C19CYP3A4MAOB | |
| SCHEMBL18770266 | 0.81 | CALML3 (0.51) | CALML3MAOACYP2C19CYP3A4MAOB | |
| SCHEMBL18770268 | 0.81 | CALML3 (0.51) | CALML3MAOACYP2C19CYP3A4MAOB | |
| SCHEMBL6023468 | 0.81 | CALML3 (0.49) | CALML3MAOACYP2C19CYP3A4MAOB | |
| SCHEMBL6023470 | 0.81 | CALML3 (0.49) | CALML3MAOACYP2C19CYP3A4MAOB | |
| SCHEMBL3166248 | 0.79 | MAOA (0.58) | CALML3MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129259-B2 | Halogenated biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060148869-A1 | Halogenated biaryl heterocyclic compounds and methods of making and using the same | CHEN SHILI | 2006-07-06 | — | — | US | disclosed |
| US-20050153971-A1 | Halogenated biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153971-A1 | Halogenated biaryl heterocyclic compounds and methods of making and using the same | PROKR1, PROKR2, PCNA | CALML3 4062/4885MAOA 1365/4885CYP2C19 745/4885 |
| US-20060148869-A1 | Halogenated biaryl heterocyclic compounds and methods of making and using the same | PCNA, PROKR1, BCOR | CALML3 4101/4885MAOA 1171/4885CYP2C19 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.